Benefits
Sleep onset latency — modest effect in adults
In primary sleep disorders, melatonin reduces sleep onset latency by approximately 7 minutes and increases total sleep time by approximately 8 minutes vs placebo — effect sizes that are statistically significant but clinically modest. Dose-response analyses indicate effect peaks at 4 mg/day administered 3 hours before bedtime. Honest framing: effect is much smaller than benzodiazepines or Z-drugs, but with a far better long-term safety profile.
Children and adolescents — stronger evidence than adults
Pooled analysis of 24 trials found melatonin significantly improves sleep onset latency and total sleep time in children and adolescents with chronic insomnia, but not in adults with non-comorbid insomnia. Particularly effective in pediatric autism spectrum disorder (ASD), ADHD, and neurodevelopmental disorders where intrinsic melatonin signaling may be disrupted. One of the few sleep aids with evidence-based pediatric use.
Jet lag — strongest single indication
Cochrane review supports melatonin for jet lag, particularly when crossing 5+ time zones eastward (the direction with the worst circadian disruption). Standard protocol: 0.5-3 mg at destination bedtime starting day of arrival, continuing for 2-5 days. Reduces jet lag severity (fatigue, daytime drowsiness, sleep disturbance) and accelerates circadian re-entrainment. One of the few sleep applications where melatonin's evidence is robust and consensus-supported.
Shift work sleep disorder
Modest evidence for daytime sleep improvement in night-shift workers when taken before daytime sleep periods. Effect is on subjective sleep quality and total daytime sleep duration. Doesn't fully resolve circadian misalignment — best used as adjunct to bright-light therapy and proper sleep hygiene rather than a standalone solution. AAFP guidelines include melatonin as a reasonable option for shift work sleep disorder.
Eye health and AMD — observational signal only
A large retrospective cohort of 121,523 adults aged 50+ found melatonin use associated with 58% lower age-related macular degeneration (AMD) development risk and 56% lower nonexudative-to-exudative progression risk. Critical caveat: this is observational data only, not a controlled trial. Hypothesis-generating, not causally established. Mechanism plausibility: melatonin is produced locally in retina, declines with age, and has antioxidant and anti-VEGF activity.
Preoperative anxiety reduction
Pooled analyses show melatonin (3-5 mg, 60-90 min preoperatively) reduces preoperative anxiety scores comparable to midazolam in some studies, with less postoperative grogginess. A reasonable option for surgical anxiety, particularly in older adults where benzodiazepine grogginess is undesirable. Effects on postoperative pain and opioid requirement have also been reported but with less consistent data.
Cancer-related fatigue (adjunctive oncology)
Multiple trials in chemotherapy and radiotherapy patients show modest reductions in cancer-related fatigue with melatonin at typically 20-40 mg/day — much higher than sleep doses. Mechanism involves antioxidant, anti-inflammatory, and circadian effects. Italian oncologist Paolo Lissoni's research program contributed much of this evidence; independent replication exists but remains limited. Best framed as adjunctive supportive care, not a cancer treatment.
Migraine prevention — preliminary
Smaller trials report 3 mg melatonin nightly reduces migraine frequency comparable to amitriptyline 25 mg with fewer side effects. Evidence base is smaller than for established preventives like topiramate or CGRP antagonists. A reasonable adjunct for those preferring melatonin's safety profile, but not first-line per current migraine prevention guidelines.
Most products contain the wrong dose
An independent quality analysis found 71% of US melatonin supplements deviated by ≥10% from label claim, with actual content ranging from -83% to +478% of the labeled amount. Many retail tablets contain 5-10 mg — far above physiological doses (0.3-1 mg). Practical recommendation: choose USP-verified products and start at 0.5-1 mg. Higher doses do not produce stronger sleep effects and may cause next-day grogginess.
Mechanism of action
Circadian rhythm regulation
Melatonin binds MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus — the master circadian clock — signaling biological darkness and synchronizing the body's sleep-wake cycle with the day-night cycle. Endogenous secretion is suppressed by light (especially blue wavelengths) and rises in darkness.
Sleep onset facilitation via SCN inhibition
By activating melatonin receptors in the SCN, melatonin inhibits wake-promoting signals from the ventrolateral preoptic nucleus, reducing alertness and facilitating sleep initiation. Unlike benzodiazepines and Z-drugs, melatonin doesn't directly cause sedation — it shifts the circadian phase and removes wake drive, allowing natural sleep onset.
Direct and indirect antioxidant activity
Melatonin directly neutralizes reactive oxygen and nitrogen species and upregulates endogenous antioxidant enzymes (superoxide dismutase, glutathione peroxidase, catalase). It crosses cell membranes and the blood-brain barrier easily, providing antioxidant protection in tissues where other antioxidants don't reach efficiently. The antioxidant role may underlie some non-sleep applications.
Anti-inflammatory effects
Melatonin inhibits pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) and modulates NF-κB signaling — a central inflammatory pathway. These effects extend to the brain, immune system, and peripheral tissues, contributing to melatonin's broader proposed applications beyond sleep.
GABA and serotonin modulation
Melatonin enhances GABA-A receptor activity, contributing to its calming and anxiolytic effects (relevant for preoperative anxiety applications). It may also modulate serotonin levels indirectly — melatonin is synthesized from serotonin via N-acetyltransferase and 5-HIOMT — contributing to mood regulation and sleep architecture.
Neuroprotective and retinal effects
By reducing oxidative stress and stabilizing neuronal membranes, melatonin protects brain cells in models of neurodegeneration. The retina specifically produces its own melatonin, with levels declining with age — this local production decline may be mechanistically relevant to age-related macular degeneration risk.
Autonomic nervous system regulation
Melatonin reduces sympathetic nervous system activity and increases parasympathetic tone, contributing to lower heart rate, blood pressure, and the overall physiological 'wind-down' that precedes sleep. May explain the modest antihypertensive effects reported in some trials.
Immune system modulation
Melatonin influences immune cell function — enhancing T-cell activity, supporting natural killer (NK) cell function, and balancing pro- and anti-inflammatory cytokine production. Mechanism behind some of melatonin's proposed adjunctive oncology and immune-support applications, though clinical evidence in healthy adults is limited.
Clinical trials
Evidence review and dose-response pooled analysis of melatonin supplementation for sleep outcomes. Modern methodology evaluating both dose-response and timing-response relationships. Published in Journal of Pineal Research.
1,689 observations across 26 clinical trials published 1989-2020. Various adult populations.
Sleep onset latency reduction and total sleep time increase both peak at approximately 4 mg/day. Timing is critical: 3 hours before bedtime produces the maximum effect, vs the more common 30-60 minute pre-bedtime use. Establishes both optimal dose and timing for harder sleep cases beyond the typical sleep hygiene context.
Pooled analysis specifically stratifying melatonin trials by age group (children/adolescents vs adults) and by insomnia type (non-comorbid vs comorbid). Published in Sleep Medicine Reviews. Addresses long-standing ambiguity about melatonin's age-specific efficacy.
1,912 participants across 24 clinical trials (20 non-comorbid insomnia + 4 comorbid insomnia).
Significant improvement in sleep onset latency and total sleep time in children and adolescents. Not significantly effective in adults with non-comorbid insomnia. This finding has important implications: many marketing claims about melatonin for adult sleep don't have meta-analytical support, but the pediatric evidence is genuinely strong.
Pooled analysis of randomized controlled trials of melatonin supplementation for primary sleep disorders. Published in PLOS One. Established the broadly-cited 'modest but real' effect size for melatonin in general adult populations.
1,683 subjects with primary sleep disorders across 19 clinical trials.
Sleep latency reduced by approximately 7 minutes (WMD -7.06, 95% CI -9.75 to -4.37, p<0.001). Total sleep time increased by approximately 8 minutes (WMD 8.25, p=0.013). Sleep quality improved modestly. Effect sizes are statistically significant but clinically modest — much smaller than prescription sleep medications, with much better safety profile.
Retrospective cohort analysis using the TriNetX electronic medical records database to evaluate associations between melatonin use and AMD outcomes. Published in JAMA Ophthalmology. Observational design with appropriate propensity-score matching.
121,523 adults aged 50+. Sub-analysis of 66,253 with existing nonexudative AMD.
Melatonin use associated with 58% reduction in AMD development risk (HR 0.42) and 56% reduction in nonexudative-to-exudative AMD progression. Critical caveat: this is observational data, not a controlled trial — strong unmeasured confounding is plausible. Hypothesis-generating for future controlled trials, not yet establishing causation.
Multiple pooled analyses of melatonin supplementation specifically in children with autism spectrum disorder (ASD) — the population with the strongest pediatric sleep evidence. Includes both immediate-release and extended-release formulations across the pediatric dose range.
Children and adolescents with autism spectrum disorder and sleep disturbance across multiple trials.
Melatonin at 1-10 mg reduces sleep onset latency by 28-39 minutes and increases total sleep by 22-50 minutes in children with ASD — much larger effect sizes than in adult populations. Effects emerge within weeks and are sustained with continued use. Strongest pediatric evidence base in melatonin research; foundational for current neurodevelopmental sleep treatment protocols.